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cancer tissue. If this study had included the SDF-1α specific 
receptor CXCR4 expression level, the authors would have ob-
tained better results. Nevertheless, the results are quite impres-
sive. SDF-1α expression was highly correlated with pericolic 
lymph-node metastasis, distant metastasis, tumor-node-me-
tastasis stage and lymphovascular invasion. Strong SDF-1α ex-
pression was inversely related with patients’ survival, suggest-
ing suggest SDF-1α could be a prognostic factor. Further study 
evaluating the distinctive value of SDF-1α expression in clini-
cal practice may be warranted. 
According to the literature, it is evident that manipulation of 
this pathway represents a new strategy for cancer treatment. 
CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 
analogues (TN14003/BKT140), and blocking antibodies toward 
CXCR4 or SDF-1α are being investigated in various cancer set-
tings. In an in vitro study using a colorectal cancer cell line, 
results indicate that a CXCR4-antagonistic therapy might pre-
vent tumor cell dissemination and metastasis in CRC patients, 
consequently improving survival [5]. Of course, we need to 
bear in mind that although targeting CXCR4/CXCL12 is an 
attractive option in treating human tumors, it is certain that 
to gain effective, reliable, and consistent clinical efficacy, a de-
finitive combinatorial therapeutic regimen should be found.
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The chemokine stroma-derived factor (SDF-1α/CXCL12) is a 
homeostatic chemokine. The major function of this chemo-
kine is to regulate hematopoietic cell trafficking and second-
ary lymphoid tissue architecture [1]. SDF-1α is also widely 
expressed in various organs. Including the heart, liver, brain, 
kidney, skeletal muscle, and lymphoid organs, and it plays mul-
tiple roles in tumor pathogenesis. SDF-1α has been demon-
strated to promote tumor growth, enhance tumor angiogene-
sis, participate in tumor metastasis, and contribute to immu-
nosuppressive networks within the tumor microenvironment. 
SDF- 1α expression is reported in ovarian cancer, breast can-
cer [2], colorectal cancer, pancreatic cancer, prostate cancer, 
thyroid cancer, and many other human tumors. 
SDF-1α can increase the invasiveness and the migration of 
cancer cells, and its levels are correlated with node involvement 
and long-term survival in patients with breast cancer. SDF-1 
may, therefore, have potential value in assessing clinical out-
comes of patients with breast cancer [3]. Although colorectal 
cancer (CRC) tissues contain SDF-1α-positive stromal cells, 
immunohistochemistry clearly demonstrated that the cancer-
ous cells in more than 50% of the CRC samples examined had 
much stronger expression of SDF-1α than their neighboring 
normal colonic epithelial cells. Accordingly, as with CXCR4 
overexpression, the SDF-1α/CXCR4 pathway appears to play 
important roles in the progression of CRC [4].
In this study, the authors merely measured the SDF-1α ex-
pression level in the normal colonic mucosa and in colorectal 
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